Myo-inositol for PCOS: what the research actually shows

If PMOS (PCOS) has an unofficial supplement, it’s myo-inositol. It headlines forum threads, fills pharmacy shelves in combination sachets, and gets recommended in group chats with the confidence of a prescription. Which makes it a perfect case study in a harder question: what does the research actually show - and what’s still hope wearing a lab coat?

First, what is it?

Myo-inositol is a naturally occurring sugar-like compound your body makes and food contains. Inside your cells, it works as a messenger in - among other things - the insulin signalling chain. That’s the logic of its use in PMOS: if insulin signalling runs smoother, the chronically high insulin that drives much of the condition may ease, and with it some of the downstream effects on ovulation and androgens. It’s often sold combined with a related form, D-chiro-inositol, most commonly in a 40:1 ratio chosen to mirror the body’s own proportions.

What the research genuinely supports

Insulin sensitivity. Multiple randomised trials and meta-analyses report that myo-inositol can improve markers of insulin resistance - fasting insulin and calculated resistance scores - compared with placebo. The effect is real but generally modest, and it shows up most clearly in women who have meaningful insulin resistance to begin with.

Ovulation and cycles. Several trials report more frequent ovulation and improved cycle regularity in women taking myo-inositol versus placebo. For a condition whose central fertility problem is irregular ovulation, that finding is genuinely encouraging - and it’s the main reason the supplement earned its place in the conversation.

Safety and tolerability. At commonly studied doses, side effects are mild and uncommon - one honest reason it’s so widely tried.

Where the evidence gets thin

Here’s the part the packaging doesn’t mention. A Cochrane review - the strictest tier of evidence assessment - looked at inositol for subfertile women with PCOS and found the evidence for the outcomes that matter most, like clinical pregnancy and live birth, to be of low quality and insufficient to draw firm conclusions. Many trials are small, short, and measure hormones rather than babies. Improving a lab marker is not the same as improving the outcome you actually care about.

The 2023 international PMOS guidelines land in a similar place: inositol could be considered, but the evidence is limited, and - critically - it should not be treated as a replacement for medical treatments with stronger evidence behind them. There’s also a practical wrinkle: supplements aren’t regulated like medicines, so the dose and ratio on the label aren’t always what independent testing finds inside.

How to think about it sensibly

A fair summary: myo-inositol is a plausible, generally well-tolerated supplement with real but modest supporting evidence for ovulation and insulin sensitivity, and unproven benefit for pregnancy and live birth. It is neither snake oil nor a cure. Where it might fit for you depends on your phenotype, your insulin resistance, your fertility timeline, and what else is in your plan - which is why the worst way to take it is silently, instead of care, while months pass.

The honest questions to bring to a specialist: Do my labs suggest the insulin resistance this supplement targets? Is there a reason to prefer it, or better-evidenced options first? How will we know in three months whether it’s doing anything? Those answers exist - they just live in your data, not in a forum thread.